CCN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Crit Care Nurse 1993 Nov; 14(6): 47-53
This Article
Right arrow Respond to This Article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Raymond, B.
Right arrow Articles by Gimesky, J
Right arrow Search for Related Content
PubMed
Right arrow Articles by Raymond, B.
Right arrow Articles by Gimesky, J
Critical Care Nurse, Vol 14, Issue 6, 47-53
Copyright © 1993 by American Association of Critical Care Nurses

Articles

Interleukin-2 therapy: needs of the patient in a critical care setting

BA Raymond, PE Haney, and J Gimesky

IL-2 is a biotherapeutic drug and a biological response modifier. This drug has not been approved by the Food and Drug Administration for general use but continues to undergo clinical trials. Candidates for this therapy are patients with advanced carcinoma that has not responded to standard modalities of treatment. Administration of IL-2 can lead to systemic toxicity, which usually appears to be dose-related. As a result, high-dose therapy requires intensive care. The critical care nurse assesses and documents side effects that occur as a result of IL-2 therapy and must be aware of both the physical and psychological needs of the patient. Through successful assessment and intervention, the nurse can gain the knowledge required to manage, both physically and psychologically, patients who are undergoing this therapy.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American Association of Critical-Care Nurses.